UBS raised its price target on Buy-rated Jazz Pharmaceuticals (NASDAQ: JAZZ) from $80 to $87, saying while Q2 missed, fundamentals ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE